Goldenwell Biotech, Inc.
GWLL
$3.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 37,400.00% | -- | 0.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 37,400.00% | -- | 0.00% | -- |
| Cost of Revenue | -- | -- | -- | -200.00% | -- |
| Gross Profit | -- | 37,400.00% | -- | 75.00% | -- |
| SG&A Expenses | 47.14% | -15.24% | 11.38% | -1.55% | -41.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.14% | -15.42% | 11.38% | -2.56% | -41.34% |
| Operating Income | 71.90% | 93.51% | -11.38% | 3.05% | 40.68% |
| Income Before Tax | 65.37% | 89.58% | -10.61% | -29.11% | 34.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 65.37% | 89.58% | -10.61% | -29.11% | 34.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 65.37% | 89.58% | -10.61% | -29.11% | 34.75% |
| EBIT | 71.90% | 93.51% | -11.38% | 3.05% | 40.68% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 50.00% | 80.00% | 0.00% | -50.00% | 50.00% |
| Normalized Basic EPS | 0.00% | 100.00% | 0.00% | -100.00% | 50.00% |
| EPS Diluted | 50.00% | 80.00% | 0.00% | -50.00% | 50.00% |
| Normalized Diluted EPS | 0.00% | 100.00% | 0.00% | -100.00% | 50.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |